Aimmune Therapeutics Inc (AIMT) Insider Douglas T. Sheehy Sells 1,648 Shares

Aimmune Therapeutics Inc (NASDAQ:AIMT) insider Douglas T. Sheehy sold 1,648 shares of Aimmune Therapeutics stock in a transaction on Monday, February 5th. The shares were sold at an average price of $35.87, for a total value of $59,113.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) opened at $37.62 on Thursday. Aimmune Therapeutics Inc has a 52 week low of $15.97 and a 52 week high of $40.65. The company has a market capitalization of $1,910.00 and a price-to-earnings ratio of -16.08.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09. equities research analysts predict that Aimmune Therapeutics Inc will post -2.51 EPS for the current fiscal year.

Several research firms have recently commented on AIMT. BidaskClub raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Royal Bank of Canada began coverage on Aimmune Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $55.00 target price for the company. Roth Capital lifted their target price on Aimmune Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Zacks Investment Research raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Credit Suisse Group set a $45.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, January 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. Aimmune Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $57.25.

Several institutional investors have recently made changes to their positions in AIMT. Schwab Charles Investment Management Inc. lifted its holdings in Aimmune Therapeutics by 21.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 105,689 shares of the biotechnology company’s stock worth $2,173,000 after acquiring an additional 18,632 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Aimmune Therapeutics by 16.9% during the second quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock worth $2,700,000 after acquiring an additional 19,016 shares in the last quarter. Legal & General Group Plc lifted its holdings in Aimmune Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 1,634 shares in the last quarter. Teachers Advisors LLC lifted its holdings in Aimmune Therapeutics by 42.1% during the second quarter. Teachers Advisors LLC now owns 63,037 shares of the biotechnology company’s stock worth $1,296,000 after acquiring an additional 18,688 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its holdings in Aimmune Therapeutics by 34.1% during the second quarter. TIAA CREF Investment Management LLC now owns 95,247 shares of the biotechnology company’s stock worth $1,958,000 after acquiring an additional 24,226 shares in the last quarter. 73.54% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/08/aimmune-therapeutics-inc-aimt-insider-douglas-t-sheehy-sells-1648-shares.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply